Korean Chinese Japanese
  • Economy
  • Politics
  • Society
  • Securities
  • Real estate
  • Culture
  • Entertainment
  • Sports
  • Opinion
Korean Chinese Japanese
Economy Corporation Pharma & Bio
Society Politics IT·Science
Securities Real Estate Global
Opinion Entertainment Sports Culture
Video Auto in Golf in
PHARM EDAILY Market in TheBeLT
Pharma & Bio
Technology

Peptron Plunges on Lilly Deal; Hanmi Falls 10% Despite Drug Approval [K-Bio Pulse]

South Korea’s pharmaceutical and biotech stocks posted mixed results on Oct. 8, with Peptron plunging nearly 30% after its technology evaluation with Eli Lilly concluded without a follow-on commercial…
  • 2026-10-10 08:02:02
  • KIM SUNG-JIN
Lifestyle

Plague Fears Boost Diagnostics; Peptron Plummets [K-bio pulse]

South Korean diagnostic stocks, including Humasis, GC Green Cross MS, and Genematrix, rallied on Tuesday as investors reacted to a suspected plague exposure incident at a Russian research institute.Th…
  • 2026-10-09 08:01:04
  • Kim Jinsoo
Technology

Yuhan Reduces Overseas Clinical Trials for ‘Post-Lecraza’ from 6 to 2… Impact on U.S. Approval Strategy

Yuhan(000100)Overseas clinical trials for “YH32367” (nesprotamig), a bispecific antibody anticancer drug being developed by the company as a “post-Lecraza” (generic name: lazertinib) candidate, are be…
  • 2026-10-09 07:31:03
  • KIM SUNG-JIN
Lifestyle

Kim Tae-yu, CEO of IMBdx, Inc.: “We Will Make Liquid Biopsy Cancer Diagnosis More Accessible by Lowering Costs and Improving Accuracy”

“Multiple Cancer Early Detection (MCED) must evolve into a test that more people can undergo regularly, rather than a one-time, expensive procedure. The key to making it widely accessible is incorpora…
  • 2026-10-09 07:21:02
  • Kim Jinsoo
Technology

Nam Yu-jun, Vice President of Ipsel: “We Must Start Planning MuCon’s Clinical Trials in Japan Together Now” [BioJapan 2026]

Nam Yu-jun, Vice President of Ipsel, sat down for an interview with Edaily on the 7th at “Bio Japan 2026” in Yokohama, Japan. (Photo: ReporterMinji Son ) “This year’s ‘BIO JAPAN 2026’ marks the fi…
  • 2026-10-09 06:01:02
  • Minji Son
Lifestyle

“‘Loresibint’ Enters European Approval Review”… SamilPharmaceutical Expected to Benefit as the World’s First DMOAD

SamilPharmaceutical(000520)Lorecivivint, a new drug for knee osteoarthritis for which the company holds exclusive domestic rights, has officially entered the European new drug approval review process.…
  • 2026-10-08 13:02:02
  • KIM JI-WAN
Technology

While Patents Have Been Successively Invalidated in the U.S., Infringement Has Been Recognized in Europe… A Wild Card in Alteogen Inc.’s ‘ALT-B4’ Patent Battle

Alteogen Inc.(196170): Judgments in the U.S. and Europe are diverging in the global patent dispute surrounding "ALT-B4," a technology for converting Keytruda into a subcutaneous (SC) formulation. “…
  • 2026-10-08 11:32:02
  • KIM SAE-MI
Lifestyle

Kim Seong-yeon, Largest Shareholder of OSCOTEC Inc., Seeks Board Seat: “No Will to Change the Board; I Will Take Action Myself” [only-EDAILY]

Kim Seong-yeon, a director at Genosco and the only son of former OSCOTEC Inc. founder Kim Jeong-geun as well as the largest shareholder of OSCOTEC Inc.(039200), is moving to restructure the board of d…
  • 2026-10-08 08:31:01
  • Kim Jinsoo
Technology

Lee Jae-hyuk, CEO of Selac Bio: "Signed Contracts with Six Filler CMO Companies… Targeting Up to 20 Billion Won in Revenue Next Year"

Cellac Bio has secured six contract manufacturing organization (CMO) clients for fillers ahead of the launch of its new plant in Wonju. The company is also in discussions for four additional contract …
  • 2026-10-08 08:01:02
  • NA EUN-KYUNG
Technology

‘Rivoceranib Hopes’ Boost HLB Affiliates; Samchundang Rises for the Fifth Consecutive Day [K-Bio Pulse]

Shares of HLB affiliates surged across the board on Oct. 6 after the U.S. Food and Drug Administration (FDA) approved an anticancer drug developed by the Korean group, while Samchundang Pharm continue…
  • 2026-10-08 07:37:02
  • KIM SUNG-JIN
prev 11 12 13 14 15 16 17 18 19 20 next

PHARM EDAILY

Shorts

EDAILY
  • 92, Tongil-ro, Jung-gu, Seoul, Korea
  • +82 2 3772 0114
  • webmaster@edaily.co.kr

※ This article has been translated using AI technology for the convenience of readers.

EDAILY provides this translation on an “as is” basis and makes no warranties, express or implied, regarding its accuracy, reliability, completeness, merchantability, or fitness for a particular purpose.
Due to the limitations of machine translation, the translated content may differ from the original Korean article. In the event of any discrepancy, the original Korean version shall prevail.
EDAILY shall not be liable for any loss or damage arising from the use of, or reliance on, the translated content.

© 2026 Copyrights by edaily. All Rights Reserved.
Korea China Japan
English